mLabs  BNP

Rapid Evaluation for Congestive Heart Failure

 

 

To date, echocardiography has been used to diagnose cardiovascular diseases, and it is one of the most widely used diagnostic tests for heart failure (HF). An echocardiogram is labor-intensive and thus expensive in comparison with biochemical markers such as BNP.

 

Micropoint’s BNP product is an in-vitro dagnostic test that offers early, rapid insight into cardiovascular function and prognosis. Using this assay clinical staff can quickly rule out congestive heart failure, can reduce unnecessary hospital admissions, costs, and length of stay, and improve clinical outcomes.

 

Micropoint’s BNP offers the advantages of speed, simplicity and stability. With whole blood sample testing no lab equipment is required, although plasma and serum are acceptable also. Results are stable after 4-10 minutes.

 

Clinical Applications:

  • Early detection, diagnosis and evaluation of severity of heart failure

 

BNP Resources:

 

Datasheet

Control Insert

Assay Insert 

Training Video

 

mLabs BNP test is CE marked and distributed outside of the US.

 

 

 

To contact Micropoint to find out more or to purchase the mLabs BNP test, please email: info@micropointbio.com.

®

 

 

U.S. Headquarters

 

Micropoint Bioscience, Inc.
3521 Leonard Court 
Santa Clara, CA 95054
United States

 

T:+1 (408) 588-1682
F:+1 (408) 588-1620

 

 

European Office

 

Micropoint Bioscience, Inc.

2 rue Eugene Sue

38100 Grenoble

France 

 

T: +33 6 22 38 20 48

F: +33 4 76 09 03 50

Asian Office

 

Micropoint Biotechnologies Co., Ltd.

5F, Bldg 1

Runheng Dingfeng Industrial Park, Liuxian 2 Rd.

Shenzhen 518101, Guangdong

China

 

T: +86 755 21600849

F: +86 755 86673903

Copyright Micropoint Biosciences 2016

Micropoint Bioscience products are not available for sale nor marketed in the United States at this time.